Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2001

View Archived Issues

Protalex completes preclinical studies with new arthritis pharmaceutical

CREB-based drugs enter animal testing for improving memory

InKine expands marketing effort for oral purgative preparation to Europe

Pangene's DNA repair protein inhibitors reverse resistance in human cancers

Company Profile: EyeTech Pharmaceuticals

Schering AG acquires rights to Refludan from Aventis

Research on promising antiobesity agents presented at NAASO meeting

FAUC-179 discovered at German university as potent and selective D4 partial agonist

Potent, selective, orally bioavailable aggrecanase inhibitor discovered at DuPont

New study finds chromium picolinate plus biotin controls blood sugar levels in type 2 diabetics

GW-3333: an oral TACE/MMP inhibitor with good activity in chronic arthritis

Genmab and Immunex to codevelop antibody therapeutics for lymphoma

FDA grants orphan drug designation to Celgene's Revimid for multiple myeloma

New triple therapy for H. pylori eradication submitted for approval on two fronts

AMDL acquires combination immunogene therapy technology

Studies in transgenic mice demonstrate positive effects of AMPAkines in ADHD

ABX-CBL promising for the management of GVHD according to phase II trial

New adenosine A2A receptor agonists reported to be particularly useful in respiratory disorders

Tularik designs LXR receptor modulators and discusses possible uses thereof

Marine sponge-derived and synthetic antitumor compounds patented by Pharma Mar

GSK developing inhibitors of Lp-PLA2 for atherosclerosis

Antiviral pyrazine derivatives in the Toyama pipeline

Potential treatments for Alzheimer's disease recently presented by DuPont

Yamanouchi patents new series of antitumor agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...